Mini-Antibodies Reactivate the Genome’s Guardian Protein
For decades, oncology has been locked in a frustrating game of “whack-a-mole.” We identify a specific mutation, design a precision molecule to target it, and then discover that the mutation is too rare or too varied to make the drug a broad-spectrum success. But a new breakthrough targeting the “guardian of the genome,” p53, suggests … Read more